# Beyond Horizons, Forward Together | Kexing Biopharm Concludes Participation in CPHI & PMEC China 2026

- Link: https://www.thailand-business-news.com/pr-news/beyond-horizons-forward-together-kexing-biopharm-concludes-participation-in-cphi-pmec-china-2026
- Published: 2026-06-24T10:53:00+07:00
- Author: PR Newswire

|   |

SHENZHEN, China, June 24, 2026 /PRNewswire/ — From June 16 to 18, the CPHI & PMEC
China 2026 was held at the Shanghai New International Expo Center. Kexing Biopharm(
688136.SH) showcased multiple self-developed innovative drug pipelines and over 
30 products for international markets at the exhibition. The company was also invited
to attend the CPHI Award ceremony and received the R&D Innovation Award for its 
achievements in innovation and international development.

**Multi-field Product Coverage and Recognition with Innovation Awards**

Its exhibited products spanned the fields of oncology, autoimmunity, and metabolic
diseases. Blockbuster drugs such as albumin-bound paclitaxel, bevacizumab, infliximab,
enzalutamide, aflibercept, liraglutide, and semaglutide received extensive consultations.

Regarding the R&D pipeline, Kexing Biopharm highlighted several global innovative
drug pipelines, encompassing GB18 for cancer cachexia, GB19/GB26 for systemic lupus
erythematosus, GB10 for ophthalmology, and GB20/GB24 for autoimmune disorders. In
addition, the clinical progress for two Phase III programs—long-acting GC and GB05(
interferon inhalation solution)—garnered significant attention.

Years of steady development in technology platforms and innovative breakthroughs
culminated in the company being honored with the R&D Innovation Award. Collaboratively
presented by the organizers and industry authorities, this award employs a multi-
dimensional assessment covering R&D innovation, clinical translation breakthroughs,
technological application, and market impact. It serves as both a recognition of
industrial innovation achievements and an insight into future trends and directions
in pharmaceutical R&D.

**Gathering at Forums to Accelerate International Business Matchmaking**

At this event, the BD team of Kexing Biopharm was highly involved in premier forums
and roundtables dedicated to global pharmaceutical expansion. By exploring cutting-
edge issues like the international commercialization of Chinese biopharmaceuticals,
the team highlighted the company’s platform successes. These exchanges provided 
vital industry perspectives and references for optimizing the company’s internationalization
pathways and seizing global market opportunities.

On the evening of June 15, Kexing Biopharm hosted a gathering for customers and 
partners from multiple countries. Participants engaged in relaxed yet in-depth discussions
on market dynamics, cooperation prospects, and future strategic planning, laying
a solid foundation of mutual trust and win-win collaboration for future endeavors.

CPHI provides a strategic platform for Kexing Biopharm to showcase its strengths
and forge connections with the global pharmaceutical market. Moving forward, the
company will continue to deepen its global presence and collaborate with global 
partners to bring more high-quality products to a broader international market.

 

---

  |  This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |

---

 
**Read the original article :** [Beyond Horizons, Forward Together | Kexing Biopharm Concludes Participation in CPHI & PMEC China 2026 ](http://www.prnasia.com/story/archive/4991039_AE91039_0?rand=184833)
